Report #2858223

Overview

Sex

Female

Age

Age unknown

State

VA

Recovered

Unknown

Vaccinated

—

Onset

—

Days to onset

—

Hospital days

—

Symptoms (2)

Symptom narrative

sore arm; down with energy; This is a spontaneous report received from a Consumer or other non HCP from medical information team. A 72-year-old female patient received BNT162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PAIN IN EXTREMITY (non-serious), outcome "unknown", described as "sore arm"; ASTHENIA (non-serious), outcome "unknown", described as "down with energy". The information on the batch/lot number for BNT162b2 omi xbb.1.5 will be requested and submitted if and when received. Additional information: The caller reported that she had multiple sclerosis for 30 years and received the original Pfizer Covid-19 vaccine in 2020, followed by six booster doses from Pfizer. She stated that she did not experience any problems and tolerated them well, with only flu shottype responses. She then received her seventh booster dose with the Moderna Covid-19 vaccine, which activated her multiple sclerosis and required steroid treatment due to complications. Her neurologist advised her against receiving further Covid-19 vaccines, and this advice had been given two years earlier. She remained ambulant but did not want to risk reactivating her multiple sclerosis and had sought advice on whether she should receive the new vaccine. She verified the information provided by the transferring agent. She explained that her final booster, which was Moderna, had activated her multiple sclerosis, while the Pfizer vaccines had only caused mild effects such as a sore arm and mild fatigue for a day, which she did not consider negative. At the time of the Moderna vaccination, she had been on an immunosuppressant, though she later clarified that she was modulated rather than immunosuppressed. She added that she wanted to inquire about the new Comirnaty vaccine to determine whether it was suitable for someone over 65 and immunomodulated, as she did not want to experience the severe reaction she had with Moderna, which left her struggling to get out of bed for a couple of weeks.The caller explained that she had never contracted Covid-19 and became concerned after reading that the new Pfizer Covid-19 vaccine was described as producing a robust response. At the time of onset, she was 68 to 69 years old, overweight, and completely mobile. She stated that the Moderna Covid-19 vaccine had severely affected her, whereas she tolerated the Pfizer vaccines well. No healthcare professional contact details were available. She had received six doses of the Pfizer Covid-19 vaccine. The first dose was given on 03 February 2021, lot EM9810, injected in the arm. The second dose was given on 26 February 2021, lot EN6198, injected in the arm. The third dose was given on 22 October 2021, lot FH8027, expiry 28 February 2022, injected in the right arm. The fourth dose was given on 10 May 2022, lot FN2908, although the final digit on the vaccination card appeared unclear, injected in the arm. The fifth dose was given on 19 May 2023, with the lot recorded as either C1 or CJ3270, injected in the arm. The sixth dose was recorded as 13 September 2022, although she thought it might have been 13 September 2023 due to a miswritten date, with the lot number documented as either 6JZ524 or 6J2524, site not specified. She reported that nothing abnormal showed up on testing and that her MRIs remained stable with no active lesions. She required steroids only after the Moderna dose. She reiterated that she had no issues with the Pfizer Covid-19 vaccines, which caused only mild reactions, but she wanted to investigate further before considering the new vaccine after reading it could cause a stronger response. The report was filed based on information provided by both the transferring agent and the caller.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202500177753 same patient/SD/AE, different dose;